NCT06495658Recruiting
Impact of Prebiotics in Ulcerative Colitis
The Clinical and Microbial Impact of Prebiotics in Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The cause of inflammatory bowel disease (IBD) is currently unknown, although partly attributed to interactions among genetic risk polymorphisms, environmental factors, gut microbiome, and host immunity. Diet, particularly those with plant-based products, have been shown in prior research to improve gut microbial composition, which has been linked to different IBD-related outcomes. This study is interested in evaluating the impact of prebiotics on gut microbiome composition and gut health in patients with IBD. Dietary composition will be assessed at baseline and over the course of 16 weeks. Participants will be randomized to either consume an 8-week course of prebiotic supplementation beginning at week 0 or week 8. Stool samples will be collected at weeks 0 and 8. The stool will be analyzed for cross-sectional and longitudinal fecal microbial changes associated with different prebiotic and diet consumption patterns in the context of heterogeneous disease characteristics.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 3 Apr 2024
- Start date
- 9 Jul 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of California, Los Angeles
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT06495658
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 9 Jul 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior colectomy
- Urgent need for abdominal surgery
Other illness
- Unstable major medical condition
- Active malignancy under treatment
Other
- Hospitalization
- Active alcohol or non-cannabinoid substance abuse
- Pregnancy or lactation
- Concerns for non-compliance
Who the study is looking for
- Ages 18 to 85 years old
- History of biopsy-proven ulcerative colitis (UC)
- Active symptoms (SCCAI \>2)
- Concomitant use of 5-aminosalicylates, immunomodulators, and corticosteroids will be permitted, although initiation or dose adjustment must not have occurred within 30 days prior to enrollment.
- Concomitant use of biologic therapy will be permitted, although initiation or dose adjustment must not have occurred within 60 days prior to enrollment.
- Prior probiotics or other dietary supplements use is permitted but will be asked to be discontinued during the course of the trial
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.